Skip to main content

Comparative Bleeding Risks Among NOAC Users for Nonvalvular Atrial Fibrillation Aged <65 years in the Sentinel System

    Basic Details
    Date
    Type
    Presentation
    Description

    Nonvitamin K antagonist oral anticoagulants (NOACs) are alternatives to warfarin for treatment of nonvalvular atrial fibrillation (NVAF). Randomized trials compared NOACs with warfarin, but not the safety of individual NOACs against each other. An FDA study using Medicare data concluded that among patients aged ≥65 years rivaroxaban had a less favorable safety profile compared to other NOACs; however, it is unclear if this safety profile persists in younger users

    This presentation compares major extracranial bleeding (MEB), gastrointestinal (GI) bleeding, and intracranial hemorrhage (ICH) in NOAC users for NVAF aged <65 years in the FDA Sentinel System. It was presented at the 2024 ISPE Annual Meeting.

     
     
    Author(s)

    Marie C. Bradley, Andrew L Simon, Joy Kolonoski, David J. Graham, Rongmei Zhang, John G. Connolly